• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

FDA approves 2 antibiotics for treating swine respiratory disease

March 3, 2022

The new prescription drugs from Merck Animal Health are broad-spectrum medications for combating organisms that cause the illness.

Officials with the FDA have approved florfenicol injectable solution (Nuflor-S; Merck Animal Health) and tulathromycin injection (Arovyn; Merck Animal Health). These broad-spectrum, prescription antibiotics treat the major organisms associated with swine respiratory disease (SRD), according to Merck.

Both drugs are prescription antibiotics indicated for use in swine, and tulathromycin injection is also indicated for cattle, according to Merck. These treatments will be available from or on the order of a licensed veterinarian in 100-mL vials (florfenicol injectable solution) and in 100-, 250- and 500-mL vials (tulathromycin injectable solution).

Florfenicol injectable solution

Florfenicol injectable solution is indicated for treatment of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Salmonella Choleraesuis, Streptococcus suis, Bordetella bronchiseptica, and Glaesserella (Haemophilus) parasuis in swine except for nursing piglets and swine of reproductive age intended for breeding.

Florfenicol injectable solution should not be used in animals intended for breeding purposes. Perianal inflammation, rectal eversion, rectal prolapse, and diarrhea may occur transiently following treatment, according to Merck. Additionally, swine intended for human consumption must not be slaughtered within 11 days of the last intramuscular treatment. Intramuscular injection may result in trim loss of edible tissue at slaughter. The effects of florfenicol on porcine reproductive performance, pregnancy and lactation have not been determined.

Advertisement

Tulathromycin injectable solution

Tulathromycin injectable solution is indicated for the treatment of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae; and for the control of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, and Mycoplasma hyopneumoniae in groups of pigs where SRD has been diagnosed.

This drug should not be used in animals known to be hypersensitive to the product. In cattle, tulathromycin injectable solution has a preslaughter withdrawal time of 18 days. This drug should not be used in female dairy cattle 20 months of age or older. In swine, the preslaughter withdrawal time for tulathromycin injectable solution is 5 days.

Reference

Merck Animal Health Receives FDA Approval of NUFLOR-S (florfenicol) and
AROVYN (tulathromycin injection). News release. Merck Animal Health. March 3, 2022.

Related Content:

FDAPharmacyInfectious Diseases
Drug for acute onset of canine pancreatitis is launched on the US market
Drug for acute onset of canine pancreatitis is launched on the US market
Gene therapy demonstrates benefit to dogs with myxomatous mitral valve disease
Gene therapy demonstrates benefit to dogs with myxomatous mitral valve disease
The impact of new guidance on compounding animal drugs
The impact of new guidance on compounding animal drugs

Advertisement

Latest News

Drug for acute onset of canine pancreatitis is launched on the US market

New Automatic 2-in-1 Pet Feeder and Water Dispenser launched

PetHub launches AI tools for pet owners

Prairie dog pups emerge from underground at Maryland Zoo

View More Latest News
Advertisement